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Abstract
CHARGE is a phenotypically heterogeneous autosomal dominant disorder recognized as a cohesive syndrome since the
identification of CHD7 as a genetic etiology. Classic features include: Coloboma, Heart defects, Atresia choanae,
Retarded growth and development, Genitourinary abnormalities, and Ear anomalies and/or deafness. With greater
accessibility to genetic analysis, a wider spectrum of features are emerging, and overlap with disorders such as
DiGeorge syndrome, Kallmann syndrome, and Hypoparathyroidism Sensorineural Deafness and Renal Disease
syndrome, is increasingly evident. We present a patient with a unique manifestation of CHARGE syndrome, including
primary hypoparathyroidism and a limb anomaly; to our knowledge, he is also the first CHARGE subject reported with
bilateral multicystic dysplastic kidneys. Furthermore, with structural modeling and murine expression studies, we
characterize a putative CHD7 G744S missense mutation. Our report continues to expand the CHARGE phenotype and
highlights that stringent fulfillment of conventional criteria should not strictly guide genetic analysis.
Introduction
The CHARGE syndrome (MIM 214800) is an autosomal
dominant or sporadic disorder of variable multisystemic
congenital anomalies that occurs with an incidence of
approximately 1 in 10,000 [1,2]. Heterozygous CHD7
(chromodomain helicase DNA-binding protein 7, MIM
608892) mutations have been identified in approximately
60%-70% of patients with clinically diagnosed CHARGE
Syndrome and are most commonly due to de novo trun-
cating mutations. Furthermore, CHD7 mutations are
reported throughout the entire coding sequence of the
gene without an apparent pattern or cluster, and mean-
ingful genotype-phenotype correlations have not been
recognized [1-3].
The first descriptions of this syndrome were provided by
Hall and Hitner independently in 1979 [4,5], though it was
in 1981 that Pagan and colleagues coined the acronym
CHARGE to summarize its dominant features: coloboma,
heart defects, atresia choanae, retarded growth and devel-
opment, genital and/or urinary abnormalities, ear anoma-
lies and/or deafness [6]. It was only in 2004 that the CHD7
gene was established as a genetic etiology for CHARGE
syndrome by Vissers et al [7]. A wider spectrum of asso-
ciated features has since emerged, albeit less consistently,
and includes hyposmia or anosmia, cleft lip and palate,
hypocalcemia [8,9], and tracheoesophageal fistula [10]. As
such, CHARGE Syndrome has several overlapping clinical
characteristics with DiGeorge syndrome [11], Kallmann
syndrome, and Hypoparathyroidism, Sensorineural Deaf-
ness, and Renal Disease (HDR) (Barakat’ss y n d r o m e )
[12,13]. As the CHARGE phenotype continues to expand,
particularly into the clinical purview of other conditions, its
diagnosis becomes more challenging as well as increasingly
inclusive.
Herein, we report a patient with a unique presentation
of CHARGE syndrome, including primary hypoparathyr-
oidism, bilateral multicystic dysplastic kidneys (MCDK),
and an atypical limb anomaly; he carried a CHD7 muta-
tion that has not been previously characterized. Our report
expands the spectrum of phenotypes associated with
CHD7 mutations.
Clinical Report
The proband, an 18 year old African American male, pre-
sented to us initially for management of refractory hypocal-
cemia. He was born weighing 795 grams at 25 weeks
gestation to a 31-year old woman with severe hypertension,
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any medium, provided the original work is properly cited.who died in the postpartum period of a myocardial infarc-
tion. In infancy, he underwent cardiac surgery for a ventri-
cular septal defect, and another to correct a right eyelid
coloboma. Additionally, he had congenital hypothyroidism,
bilateral sensorineural hearing loss, and severe global devel-
opmental delay; he began walking during his third year of
life, remains unable to independently dress or tie shoe
laces, and he has a vocabulary of fewer than 5 words. At a
young age, the family had been told that he had Down syn-
drome, a diagnosis he carried until our meeting. Our initial
consultation for hypocalcemia was during a hospitalization
for complications of end stage renal disease secondary to
MCDK, which was diagnosed in early life based on X-ray
computed tomography (CT) showing dysplastic kidneys
with multiple cysts. Interestingly, both a full sister and
maternal half sister had severe hearing deficits and renal
disease (Figure 1A). Unfortunately, neither was available
for further characterization.
His physical examination revealed an overweight and
short young man (weight 65.9kg, height 150.5cm or -3.58
SDS, body mass index 29.3 kg/m
2), communicating pri-
marily with hand gestures including pointing. He had
brachycephaly with a flat facial profile, short forehead
and facial asymmetry, slightly upslanted eyes with mild
right ptosis, a scar from eyelid coloboma corrective sur-
gery, and mildly prominent ears with low nasal bridge,
upturned nasal tip, and smooth philtrum (Figure 1B.I
and 1B.II). He had no cleft lip or palate. The chest was
symmetrical. He had scars from cardiac surgery on the
left anterior and posterior walls, and on the anterior
Figure 1 A patient with a unique presentation of CHARGE syndrome and a G744S CHD7 mutation. A. Pedigree of a CHARGE patient with
a novel CHD7 mutation. circle: female; square: male; arrow: proband; +: wild type allele. B. Photographs of the facies (I), eyes (II), and hands (III) of
the CHD7 G744S heterozygous proband. C. Evolutionary conservation of the residue Gly744. ClustalW multiple alignment of partial protein
sequence of CHD7 orthologs. The position of residue G744 altered by one heterozygous nucleotide change is marked by arrow and red letters
in the corresponding segment of the multiple alignment. The amino acid residues that differ from the sequence of the human CHD7 protein are
indicated blue. Gly744 residue is evolutionarily fully conserved in all fifteen available CHD7 orthologs. D. Structural model of the amino acid
regions spanning 651-794 of the CHD7 protein obtained by sequence homology to a bacterial flagellar filament. The site of the mutation
(indicated in magenta), which is predicted to be detrimental by POLYPHEN, lies on a protein interaction surface as indicated by SSPIDER.
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Page 2 of 8abdominal wall at the site of a neonatal gastric tube pla-
cement. On examination of the extremities, his palmar
creases were normal and he had a flexion deformity of
the right thumb whereby this digit was fixed in the
adducted position (Figure 1B.III). His genital examination
revealed Tanner V pubic hair, and bilaterally descended
testes consistent in size with early to mid-pubertal range
(5 mL right and 8 mL left, using Prader Orchidometer).
A CT scan of the head showed bilateral basal ganglia
calcifications and scattered calcification in the frontal
white matter and cerebellum, likely related to chronic
hypcalcemia. Olfactory structures could not be evalu-
ated. X-ray of his hands revealed no osseous abnormal-
ities to explain his right thumb deformity.
The initial laboratory results included low serum cal-
cium (6.3 mg/dL, normal 8.3-10 mg/dL) normal albumin
(4.2 g/dL, normal 3.5-5.8 g/dL), low phosphorus (1.1 mg/
dL, normal 2.5-5 mg/dL), normal 25-hydroxy vitamin D
(38 ng/mL, normal 20-100 ng/mL), slightly low magne-
sium (1.6 mg/dL, normal 1.9-2.7 mg/dL) coincident with
low parathyroid hormone level (4.9 pg/mL, normal 15-65
pg/mL), indicating primary hypoparathyroidism. His low
phosphorus was due to phosphate wasting associated with
polyuria of end stage renal disease (ESRD). He had normal
complete blood cell counts with no evidence of white cell
line depression. Additionally, despite having early to mid-
pubertal sized testes, his LH, FSH and Testosterone were
not in the hypogonadal range (LH 4.1 mIU/mL, FSH 6.8
mIU/mL, Testosterone 505 ng/dL), which is not consistent
with Idiopathic Hypogonadotropic Hypogonadism.
In view of his dysmorphic features and questionable his-
tory of Down Syndrome (MIM 190685), a karyotype was
obtained which showed a normal 46, XY configuration in
200 stimulated peripheral lymphocytes. Fluorescent in situ
hybridization (FISH) for a chromosome 22q11.2 deletion,
associated with DiGeorge Syndrome (MIM 188400), was
negative. To exclude a Calcium-Sensing Receptor defect
(MIM 601199), sequencing of the CASR gene was con-
ducted of the coding regions and exon/intron boundaries
and did not reveal a mutation. In light of the patient’s con-
stellation of hypoparathyroidism, renal disease, as well as
deafness, we performed microarray and then sequencing
analyses for mutations in GATA3 gene associated with the
HDR syndrome (MIM 146255) [13], and none were found.
Finally, CHD7 mutation analysis was performed on a
genomic sample after PCR amplification of exons 2 to 38.
The primers for all exons flanked the respective intron-
exon junctions and direct sequencing was performed in
both forward and backward directions using automated
fluorescence di-deoxy sequencing methods. This revealed
6 heterozygous unclassified variants in the CHD7 gene
including 2 missense and 4 silent changes (Table 1).
Among the missense changes, a G744S (NP_060250)
resulting from a c.2230G®A nucleotide change (NM-
017780), was found to be conserved in available CHD7
orthologs (Figure 1C) and was not identified in 192 con-
trol subjects. The subject’s asymptomatic father, the only
family member available for genetic analysis, was found
not to carry the G744S substitution. An informed consent
for all genetic testing and for image publication was
obtained from father and from the subject’s legal guardian.
Structural Modeling of the CHD7 Protein
The G744S mutation, which is located near chromodo-
main 1 in exon 4, was hypothesized to possess functional
implications in the pathogenesis of CHARGE Syndrome.
We constructed a structural model for the portion of the
CHD7 protein containing the mutation based on homol-
ogy to a bacterial flagellar filament (pdb-code 1UCU) [14]
(See Figure 1D and additional file 1 for methods and align-
ment). Based on this model, SPPIDER [15] identified the
site of the mutation as a possible binding site. G744 is
located at the protein surface, where mutations are most
likely to affect protein function and signaling compared to
mutations in the protein interior. In agreement with this
observation, the bioinformatics based approach POLY-
PHEN predicted a possible damaging effect of the muta-
tion with a PISC SCORE: 1.58 (values below 0.5 are
considered benign and values above 1.0 possibly/probably
damaging) [16]. The PISC score contains a sequence
based estimate of the accessibility of the mutation site,
which is underestimated in comparison with the predic-
tions of the structural model. Therefore, the sequence
based PSIC score likely underestimates the damaging
effect of our mutation.
Chd7 Murine Expression Studies
Throughout murine development Chd7 is broadly
expressed, including organs classically anomalous in
CHARGE Syndrome, such as the eyes, heart, and ears.
To investigate the distribution of Chd7 transcripts in
the developing limbs, we performed in situ hybridization
analysis using whole mount preparations. The following
Table 1 Sequence Analysis Revealed Six Unclassified
Variants in the CHD7 Gene
Nucleotide Change
NM_017780
Amion Acid Change
NP_060250
SNP ID*
Missense changes
c.2230G®A p.G744S -
c.6478G®A p.A2160T rs61753399
Silent Changes
c.309G®A p.S103S rs41272435
c.657C®T p.G219G -
c.2124T®C p.S708S -
c.7590A®G p.K2530K rs61742801
*Reported in the Single Nucleotide Polymorphism database dbSNP:http:www.
ncbi.nlm.nih.gov//SNP
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ning nucleotides 8305 to 9140 of the murine Chd7 tran-
script (NM_001081417): 5′-CAGGTGGCTGGAGGAGA
ACCC-3′ and 5′-CTTTACAGGGCCCTCCCTCGGCC-
3′. Amplicons were ligated to a Topo-TA vector (Invi-
trogen) and subcloned into pBluescript via EcoRI and
XbaI restriction sites. The probe was labeled with
Digoxigenin (DIG) for whole-mount in situ hybridiza-
tion following standard procedures. No specific signals
were detected using the respective sense probes. By
embryonic day E11.5, the limb buds are clearly divided
into proximal and distal elements. By E12, the handplate
showed evidence of angular contours at its peripheral mar-
gin, corresponding to the location of the future digits. At
E12.5-E13 early evidence of digital rays that are separated
by the digital interzones were apparent. We found high
expression levels of Chd7 throughout these steps of limb
development in DIG-labelled whole mount embryos. Pro-
nounced Chd7 expression was noted at the limb bud api-
cal ectodermal ridge (AER) (Figure 2), a thickened layer of
ectodermal cells at the distal tip of the developing limb
bud, which is a crucial organizing region during limb for-
mation. This Chd7 expression pattern supports a role for
this gene in limb development.
Discussion
CHARGE is a phenotypically heterogeneous autosomal
dominant disorder that has been recognized as a non-
random cohesive syndrome since the identification of
CHD7 mutations as an underlying etiology [1,2,7].
CHD7, at 8q12.1, encodes a protein of the chromodo-
main family [17,18]. The exact function of CHD7 has not
been elucidated, however, in situ hybridization analysis
during human development has demonstrated expression
of this gene in the central nervous system, semicircular
canals and the neural crest of the pharyngeal arches;
thereby implicating the embryologic role of CHD7 in the
development of the respective organs [19,20]. Further-
more, CHD7 mRNA expression was documented in the
hypothalamus, pituitary and olfactory bulb in the rat and
also demonstrated in both migratory and post-migratory
GnRH neuronal cell lines [21]. Our subject carried a het-
erozygous G744S, not seen in controls; this missense
change has been reported in one previous series and
designated a polymorphism, though no functional studies
were conducted and controls were not tested [22]. In this
instance, the G744S change was seen in a family with
three children with clinical CHARGE born to two differ-
ent women and one man. A larger CHD7 rearrangement
was additionally seen in all affected children, and found
in mosaic form in the father’s sperm cell DNA but not in
lymphocytes. The G744S change, however, was found in
two of the CHARGE children (the third was not tested)
and in the completely unaffected father. Since the father
was heterozygous and not mosaic for G744S, the authors
considered G744S to be a non-pathogenic variant (Kohl-
hase J, unpublished data). CHD7 mutations have clini-
cally variable expression, and clear genotype-phenotype
correlations are not observed, even among patients with
identical CHD7 mutations [1-3]. Asymptomatic carriers
are reported as well, particularly in inherited forms [3].
We can speculate that the disparate putative effect of this
mutation is subject to yet undefined secondary genetic,
epigenetic or environmental influences; this has been
demonstrated in other genetic disease models, such as
idiopathic hypogonadotropic hypogonadism (IHH) and
Kallmann syndrome [23-25]. Our bioinformatics based
structural analysis, protein alignment, and DNA sequen-
cing in normal controls, provide supportive evidence that
the G744S is a true deleterious mutation involving a
highly conserved amino acid, likely disrupting a crucial
protein interaction site.
In this age of sophisticated and readily available genetic
analysis, the diagnosis of CHARGE appears to be trans-
forming from the rigid fulfillment of conglomerates of
specific major and minor criteria, towards an approach
more inclusive of patients with atypical or attenuated
phenotypes, as was demonstrated by Kim et al [26].
CHARGE and Kallmann syndromes (KS, KAL5, MIM
612370), though distinct developmental disorders, were
noted to share features of impaired olfaction and hypogo-
nadism; thus CHD7 was hypothesized to be involved in
the pathogenesis of KS even in the absence of the
CHARGE phenotype. Among 197 patients, they identified
seven heterozygous mutations (two splice and five mis-
sense, absent in ≥ 180 controls) in three sporadic KS and
four sporadic normosmic IHH patients. Thus, sporadic
CHD7 mutations occurred in 6% of IHH/KS patients
studied, allowing them to conclude that IHH/KS can
represent a milder allelic variant of CHARGE syndrome.
Furthermore, Jongmans et al also identified de novo
CHD7 mutations in 3 of 56 mixed KS and nIHH sub-
jects. Interestingly, in retrospect, their IHH patients with
CHD7 mutations had some CHARGE features, including
colobomas, deafness, ear anomalies, cleft palate and short
stature; however, not to the degree that would fulfill tra-
ditional criteria [27]. Supported by this rational, we can
concluded that our subject, with an atypical eyelid colo-
boma, hearing loss, severe developmental delay, ventricu-
lar septal defect, short stature, and abnormal facies, in
addition to other more recently described features, such
as a limb anomaly, primary hypoparathyroidism and
interrupted pubertal development, may be included in
this designation.
CHARGE syndrome was initially not considered to
involve the limb. Several subsequent reports have shown
associated limb anomalies and one series reported at least
one limb anomaly in over one third of 172 CHARGE
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mon limb anomaly in their cohort and minor abnormalities
were included [28]. Prasad et al in 1997 were among the
first to report severe limb abnormalities, including campto-
dactyly, tibial hemimelia and severe club-foot, in a patient
with clinical CHARGE Syndrome [29]. It is notable that
“club-foot”, or congenital talipes equinovarus, is typically
not due to osseous malformation. In 2007, Van de Laar
et al reported 3 patients with heterozygous CHD7 truncat-
ing mutations in distinct exons, who displayed several limb
malformations, including tibial aplasia, monodactyly and
bifid femora [30]. Other limb defects, including triphalan-
geal thumb, polydactyly of the foot, ectrodactyly, and radial
aplasia, have been reported as well [1,19,29,31]. Sanlaville
et al in 2006, studied expression of CHD7 during human
embryonic development detecting a weak signal in limb
bud mesenchym at C14 [20]. Our patient, added to those
previously described, highlighted by our demonstration of
strong Chd7 expression in murine limb buds, further sup-
ports the suggestion that limb abnormalities should be a
more recognized feature within the phenotypic spectrum
of CHARGE syndrome. Moreover, homology modeling
revealed a similarity to a bacterial flagellae protein [14],
which in turn has high homology with the human TCN
gene, encoding the human cytoskeletal protein titin; in
concert with actin, titin plays a dominant role in human
cytoskeletal development. Interestingly, direct comparison
of titin and 1UCU sequences revealed a 19 amino acid gap
of highly charge amino acids (spanning aa 741-759,
EDPGVQKRRSSRQVKRKRY), which are most likely
involved in functional differences between the two proteins
and hence confer particular vulnerability to functional
changes upon mutation.
In CHARGE Syndrome, anomalies of the urinary tract
are reported in 10-40%, and include neurogenic bladder,
duplex kidneys, renal ectopia or agenesis, horseshoe kid-
neys, and ureteral anomalies. [1,32,33]. To our knowledge,
our patient is the first CHARGE patient to be reported
with the severe phenotype of MCDK, requiring renal
replacement therapy with dialysis followed by transplant.
Cystic renal dysplasia is an anomaly of differentiation of
the fetal kidney, whereby the kidney contains primitive
ducts and non-renal tissues such as cartilage, fat, hemato-
poietic tissue, and often cysts. The most severe form of
cystic renal dysplasia is MCDK, and most cases are unilat-
eral. In subjects with CHARGE, only few reports of simple
renal cysts exist [1,2,30]. Interestingly, one CHARGE sub-
ject with a unilateral right-sided dysplastic kidney also had
significant limb anomalies, including right tibia aplasia, left
tibia hypoplasia, and bilateral club feet [30]. The molecular
events involved in multicystic dysplastic kidneys, in gen-
eral, remain to be elucidated, though studies have
Figure 2 Chd7 expression in the developing mouse. At E11.5 Chd7 is broadly expressed and shows prominent signals with the Chd7
antisense probe in DIG labeled whole mount in-situ hybridization in the region of the distal tip of the limb buds (see also enlargements on the
right). T: telencephalic vesicle, E: corneal ectoderm overlying lens vesicle, M: maxillary component of first branchial arch, H: heart, FL: forelimb, HL:
hindlimb.
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PAX2 [36]. The PAX2 gene is associated with the renal
coloboma syndrome (MIM 120330), a syndrome charac-
terized by renal hypoplasia and insufficiency, vesicoure-
teric reflux, and optic disc coloboma. Interestingly,
multicystic dysplastic kidney has been reported in one
family with Renal Coloboma Syndrome [36]. In a study of
the distribution pattern of the PAX2 gene in human
embryos, Tellier et al demonstrated that PAX2 gene
expression occurs in the primordia affected with CHARGE
syndrome. Therefore, PAX2 was further analyzed in 34
patients fulfilling the diagnostic criteria of the CHARGE
syndrome, though no deletions or nucleotide variations of
the coding sequence were detected, suggesting that muta-
tions of the PAX2 gene was not a cause of the CHARGE
[37]. Considering the embryonic expression of PAX2
reported, and the common clinical features of Renal Colo-
boma Syndrome with CHARGE, one can hypothesize that
CHD7 may have a role in regulating PAX2 gene and there-
fore this overlapping pathway might be explored in
CHARGE etiology, and perhaps contributes to the variable
expression observed.
The significant clinical overlap and inherently variable
features of CHARGE and DiGeorge Syndromes can make
differentiating these initial diagnoses particularly challen-
ging. Hypocalcemia has been reported in CHARGE,
though hypoparathyroidism, specifically, has been impli-
cated in only few cases [38,39]. A study comparing 25
CHARGE subjects with CHD7 mutations to a large cohort
of subjects with 22q11.2 deletion syndrome, noted that
features found more commonly in CHARGE syndrome
included coloboma, choanal atresia, facial nerve palsy, tra-
cheoesophageal fistula, and genital hypoplasia in boys.
Interestingly, a high incidence of marked hypocalcemia
was observed in their CHARGE study group (72%), and a
pronounced spectrum of cell-mediated immunodeficiency
ranging from lymphopenia (60%) to severe combined
immunodeficiency (8%), was seen as well. Defects in
humoral immunity were documented in 4 CHARGE
patients and included severe hypogammaglobulinemia
with decreased T-cell numbers, transient hypogammaglo-
bulinemia during infancy, and immunoglobulin A defi-
ciency [40]. An accurate distinction between these two
entities can, therefore, be challenging but will influence
genetic counseling; CHD7 mutations more typically occur
sporadically, whereas 22q11.2 deletions are familial in 10%
of cases [2,41].
Conclusion
In summary, we report an 18 year old male with CHARGE
syndrome and a unique phenotype, including primary
hypoparathyroidism, bilateral MCDK, a limb anomaly, dis-
rupted testicular growth, and an atypical eyelid coloboma,
who harbored a heterozygous G744S CHD7 mutation.
Our case emphasizes that CHARGE features are perhaps
even more heterogeneous than previously described and
should include limb anomalies more universally. Addition-
ally, the stringent fulfillment of the conventional CHARGE
criteria should not strictly guide genetic analysis. Further-
more, our report highlights that the clinical overlap of
CHARGE with DiGeorge, HDR, and Kallmann Syndromes
can pose a diagnostic challenge to the clinician, but the
correct designation can have a critical impact on treat-
ment, anticipatory guidance, and genetic counseling.
Additional material
Additional file 1: Additional file 1includes further elaboration of
chd7 protein modeling and alignement methods, as well as one
figure of the protein sequence alignement.
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